2009
DOI: 10.1186/1475-2875-8-88
|View full text |Cite
|
Sign up to set email alerts
|

WISDOM-II: Screening against multiple targets implicated in malaria using computational grid infrastructures

Abstract: Background: Despite continuous efforts of the international community to reduce the impact of malaria on developing countries, no significant progress has been made in the recent years and the discovery of new drugs is more than ever needed. Out of the many proteins involved in the metabolic activities of the Plasmodium parasite, some are promising targets to carry out rational drug discovery.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
33
0

Year Published

2010
2010
2017
2017

Publication Types

Select...
8
2

Relationship

1
9

Authors

Journals

citations
Cited by 38 publications
(33 citation statements)
references
References 50 publications
0
33
0
Order By: Relevance
“…More than 46 million molecular structures were computer examined to find candidates with potential bioactivity. Grid based technology is now also being applied to manage databases of cancer patients which will help in assessing their treatment (Kasam et al, 2009).…”
Section: Q Applications Involving the Handling And Analysis Of Very mentioning
confidence: 99%
“…More than 46 million molecular structures were computer examined to find candidates with potential bioactivity. Grid based technology is now also being applied to manage databases of cancer patients which will help in assessing their treatment (Kasam et al, 2009).…”
Section: Q Applications Involving the Handling And Analysis Of Very mentioning
confidence: 99%
“…The WPE platform [2], developed by the LPC Laboratory in Clermont-Ferrand, France, was successfully used in the WISDOM-I (2005) and WISDOM-II (2006) projects as a layer between users and grid resources. It facilitates the massive submission of jobs to the grid.…”
Section: The Wpe Platformmentioning
confidence: 99%
“…Many experimental peptidic and nonpeptidic plm inhibitors exist and have been described in detail, along with their Ki values and often the steps of their synthesis, in a number of papers [37], . Some of these inhibitors were identified by high-throughput screening [61,67,68,69,70], by computational analysis of the plm's active site [56,62], or in natural products [57,71,72], though most are the result of rational drug design.…”
Section: Introductionmentioning
confidence: 99%